Bristol: Sales For Opdivo Are Flying High
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent approvals for Bristol’s PD-1 inhibitor Opdivo resulted in accelerated sales in the second half, with rapid adoption in new indications, says CEO Giovanni Caforio at the J.P. Morgan conference.